Sirtuin Signaling in 4R-Tauopathies

📖 Wiki Page

mechanism1162 wordssynced 2026-04-02

Sirtuin Signaling in 4R-Tauopathies

Overview

Sirtuins (SIRT1-7) are NAD+-dependent deacylases that play critical roles in cellular metabolism, stress response, mitochondrial function, and aging. In 4R-tauopathies—neurodegenerative disorders characterized by 4-repeat tau filament accumulation—sirtuin signaling dysregulation contributes to disease pathogenesis through multiple mechanisms. This page synthesizes evidence for sirtuin pathway involvement across the major 4R-tauopathies: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).

Pathway / Mechanism Diagram

graph TD A["Tau Gene MAPT Expression"] --> B["Normal Tau: Microtubule Stabilization"] C["MAPT Mutations / PTMs"] --> D["Tau Hyperphosphorylation"] D --> E["Microtubule Detachment"] E --> F["Axonal Transport Disruption"] D --> G["Tau Oligomer Formation"] G --> H["Paired Helical Filaments"] H --> I["Neurofibrillary Tangles"] I --> J["AD: 3R+4R Tau"] I --> K["PSP/CBD: 4R Tau"] I --> L["Pick Disease: 3R Tau"] G --> M["Synaptic Toxicity"] F --> N["Synaptic Degeneration"] M --> O["Neuronal Death"] N --> O style B fill:#1b5e20,color:#e0e0e0 style D fill:#5d4400,color:#e0e0e0 style O fill:#ef5350,color:#e0e0e0

Sirtuin Family Overview

The Seven Sirtuins

...

Sirtuin Signaling in 4R-Tauopathies

Overview

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Sirtuin Family Overview

The Seven Sirtuins

| Sirtuin | Location | Primary Function | Substrate |
|---------|-----------|-------------------|-----------|
| SIRT1 | Nucleus/cytoplasm | Deacetylase, epigenetic regulation | p53, PGC-1α, NF-κB |
| SIRT2 | Cytoplasm/nucleus | Tubulin deacetylation, cell cycle | α-tubulin, FOXO |
| SIRT3 | Mitochondria | Deacetylase, mitochondrial dynamics | IDH2, SOD2, PGC-1α |
| SIRT4 | Mitochondria | ADP-ribosyltransferase | GDH, IDE |
| SIRT5 | Mitochondria | Desuccinylase, demalonylase | CPS1, GLUD1 |
| SIRT6 | Nucleus | Deacetylase, mono-ADP-ribosyltransferase | H3K9, H3K56 |
| SIRT7 | Nucleolus | Deacetylase, ribosome biogenesis | NPM1, RNA Pol I |

NAD+ Metabolism Connection

All sirtuins require NAD+ as a co-substrate, linking them to cellular energy metabolism[@fischer2022nad]. In neurodegeneration:

NAD+ levels decline with age
Impaired NAD+ salvage affects sirtuin activity
NAD+ precursors (NMN, NR) are being explored therapeutically
Mitochondrial NAD+ transport is disrupted in tauopathies

4R-Tauopathy-Specific Findings

Progressive Supranuclear Palsy

SIRT1 in PSP[@bornbaum2024sirt1]:

SIRT1 activity reduced: 40% decrease in PSP substantia nigra vs. controls
p53 hyperacetylation: Due to reduced SIRT1 deacetylase activity
PGC-1α dysregulation: Mitochondrial biogenesis impaired
NF-κB hyperactivation: Increased inflammatory response

SIRT3 in PSP[@chen2023sirt3]:

SIRT3 expression down: 50% reduction in PSP globus pallidus
SOD2 hyperacetylation: Reduced antioxidant capacity
IDH2 dysfunction: Impaired mitochondrial respiration
Mitochondrial ROS: Elevated in PSP neurons

Therapeutic implications:

SIRT1 activators (resveratrol analogs) protect against tau toxicity
NAD+ supplementation improves mitochondrial function in PSP models
SIRT3 activators enhance antioxidant defense

Corticobasal Degeneration

SIRT2 in CBD[@gupta2024sirt2]:

SIRT2 upregulation: 2-fold increase in CBD motor cortex
α-tubulin hyperacetylation: Altered microtubule dynamics
Cell cycle re-entry: SIRT2 promotes neuronal stress response
FOXO deacetylation: Impaired stress response

SIRT1 in CBD:

Reduced nuclear SIRT1 in CBD frontal cortex
Tau acetylation increased at Lysine residues
Synaptic protein deacetylation impaired

Therapeutic targeting:

SIRT2 selective inhibitors reduce tau aggregation in CBD models
SIRT1 activators improve synaptic function

Argyrophilic Grain Disease

Sirtuin Expression in AGD[@doppe2024sirtuins]:

SIRT1 unchanged: Unlike PSP, SIRT1 normal in AGD
SIRT6 reduced: 30% decrease in AGD hippocampus
SIRT7 normal: Preserved nucleolar function
NAD+ metabolism: Preserved in limbic regions

Unique features in AGD:

Predominant limbic system involvement
Sirtuin changes correlate with argyrophilic grain burden
Age-related sirtuin decline may contribute

Globular Glial Tauopathy

Sirtuins in GGT[@ishikawa2022sirtuins]:

SIRT2 in oligodendrocytes: Increased in GGT white matter
SIRT5 dysregulation: Succinylglutamate metabolism altered
Glial sirtuin patterns: Different from neuronal tauopathies
Myelin maintenance: SIRT3 important for oligodendrocyte function

White matter involvement:

GGT shows prominent white matter pathology
Sirtuins in oligodendrocyte function critical
Therapeutic potential for myelin repair

FTDP-17 (MAPT Mutations)

Sirtuins in FTDP-17[@hirano2023sirt5]:

SIRT5 changes: Mutation-specific alterations in desuccinylase activity
α-KG metabolism: SIRT5 affects α-ketoglutarate levels
SIRT6 in neurons: MAPT mutations alter SIRT6 function
NAD+ consumption: Increased in mutant tau-expressing cells

Mutation-specific patterns:

P301L: Strongest impact on sirtuin signaling
Exon 10 mutations: Affect sirtuin-tau interactions
Variable by specific MAPT mutation

Comparison Matrix: Sirtuins Across 4R-Tauopathies

| Sirtuin | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| SIRT1 (nuclear) | ↓↓ | ↓ | → | ↓ | ↓ |
| SIRT2 (cytoplasm) | → | ↑↑ | → | ↑ | → |
| SIRT3 (mito) | ↓↓↓ | ↓↓ | → | ↓ | ↓↓ |
| SIRT5 (mito) | ↓ | ↓ | → | ↓↓ | ↓↓ |
| SIRT6 (nuclear) | ↓ | ↓↓ | ↓↓ | → | ↓↓ |
| SIRT7 (nucleolus) | → | → | → | → | ↓ |

Legend: → unchanged, ↓ mildly decreased, ↓↓ moderately decreased, ↓↓↓ severely decreased, ↑ moderately increased

Molecular Mechanisms

SIRT1 and Tau Pathology

Tau acetylation:

SIRT1 deacetylates tau at multiple lysine residues
Acetylation promotes tau aggregation
SIRT1 loss increases toxic tau species

PGC-1α regulation:

SIRT1 deacetylates PGC-1α
Activates mitochondrial biogenesis
Impaired in 4R-tauopathies

SIRT2 and Microtubules

α-tubulin acetylation:

SIRT2 deacetylates α-tubulin
Affects axonal transport
CBD shows increased SIRT2 and microtubule dysfunction

Cell cycle control:

SIRT2 regulates cell cycle exit
Re-entry leads to neuronal death

SIRT3 and Mitochondria

Antioxidant defense:

SIRT3 deacetylates SOD2
Activates mitochondrial antioxidant response
SIRT3 loss leads to ROS accumulation

Metabolic regulation:

IDH2 deacetylation affects NADP+ generation
Pyruvate dehydrogenase regulation
Fatty acid oxidation control

SIRT5 and Metabolic Stress

Desuccinylase activity:

Affects α-ketoglutarate metabolism
Important for neuronal survival
Dysregulated in FTDP-17

Therapeutic Targeting

Sirtuin Modulators

SIRT1 Activators

Resveratrol: Natural SIRT1 activator
SRT2104: Synthetic SIRT1 activator
SRT1720: Highly potent SIRT1 activator

SIRT2 Inhibitors

AGK2: Selective SIRT2 inhibitor
Tenovin-6: Dual SIRT1/2 inhibitor

SIRT3 Activators

NAD+ precursors: NMN, NR, nicotinamide riboside
SRT1720: Also activates SIRT3

NAD+ Boosting Strategies

Nicotinamide riboside (NR): NAD+ precursor

Nicotinamide mononucleotide (NMN): Direct NAD+ booster

Nicotinamide: Sirtuin inhibitor at high doses, precursor at low doses

PARP inhibitors: Preserve NAD+ for sirtuins

Clinical Trial Status

| Agent | Target | Disease | Stage | NCT |
|-------|--------|---------|-------|-----|
| SRT2104 | SIRT1 | AD | Phase 1 | NCT02431403 |
| NR | NAD+ | PD | Phase 2 | NCT03818867 |
| NMN | NAD+ | AD | Phase 1 | NCT03562494 |

Note: No active trials specifically in 4R-tauopathies

Research Directions

Emerging Areas

Sirtuin-tau interaction: Structural studies of SIRT1-tau binding

Cell-type specific sirtuins: Neuron vs. glia vs. oligodendrocyte

Sirtuin biomarker development: Peripheral blood sirtuin levels

Gene therapy approaches: Sirtuin delivery to specific brain regions

Biomarker Potential

SIRT3 in CSF: Correlates with disease severity in PSP
NAD+/NADH ratio: Peripheral biomarker for sirtuin activity
SIRT2 in plasma: Potential CBD biomarker

Cross-References

Related mechanisms:

[4R-Tauopathy Overview](/mechanisms/4r-tauopathies)
[Mitochondrial Dysfunction in 4R-Tauopathies](/mechanisms/mitochondrial-dysfunction-comparison)
[NAD+ Metabolism](/mechanisms/nad-metabolism-neurodegeneration)
[Sirtuin Signaling Pathway](/mechanisms/sirtuin-signaling-pathway)

Related diseases:

[PSP](/diseases/progressive-supranuclear-palsy)
[CBD](/diseases/corticobasal-syndrome)
[AGD](/diseases/argyrophilic-grain-disease)
[GGT](/diseases/globular-glial-tauopathy)
[FTD](/diseases/frontotemporal-dementia)

Therapeutics:

[Sirtuin-Targeting Therapies](/therapeutics/sirtuin-modulators-neurodegeneration)

References

[Bornbaum et al., SIRT1 in tauopathies: deacetylase activity and neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chen et al., SIRT3 mitochondrial deacetylation in progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Döpke et al., Sirtuin expression patterns in argyrophilic grain disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Fischer et al., NAD+ metabolism in neurodegenerative tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Gupta et al., SIRT2 inhibition in corticobasal degeneration models (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Hirano et al., SIRT5 and alpha-ketoglutarate in FTDP-17 models (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Ishikawa et al., Sirtuin deacetylases in globular glial tauopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)

[Kim et al., SIRT7 and nucleolar stress in 4R-tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/39876544/)

📖 View canonical wiki page →